Tevogen Bio Accelerates Growth With New Corporate Hub to Accommodate its Expanding Operations
Retrieved on:
Monday, February 7, 2022
Research, Other Health, Pharmaceutical, Oncology, Infectious Diseases, Hospitals, Genetics, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Other Science, Investigator's brochure, CTL, Intellectual property, Multimedia, Medicine, Research, Intention, Multiple sclerosis, Company, Thomas Jefferson University Hospital, Degenerative disease, Leadership, Clinical trial, Efficiency, Infection, FDA, EBV, Patient, Epstein–Barr virus, Severe acute respiratory syndrome coronavirus 2, Population, Bio, MS, Ecosystem, CTLS, Cancer, COVID-19, Pharmaceutical industry, Vaccine, Tevogen’s T cell Technology, Investigational COVID-19 Therapy and Pipeline Targets, Tevogen Bio, TEVOGEN’S T CELL TECHNOLOGY, INVESTIGATIONAL COVID-19 THERAPY AND PIPELINE TARGETS, TEVOGEN BIO
View the full release here: https://www.businesswire.com/news/home/20220207005866/en/
Key Points:
- View the full release here: https://www.businesswire.com/news/home/20220207005866/en/
Tevogen Bio new corporate hub, Warren NJ (Photo: Business Wire)
The facility, located in New Jerseys biotech corridor, will serve as the companys central location for corporate operations and was selected after thorough countrywide market research. - Tevogen CEO Ryan Saadi , M.D., M.P.H., said, Our corporate hub represents an important operational next step to best strategically support the diversification and expansion of our portfolio of T cell immunotherapies.
- Tevogen Bio is driven by a team of distinguished scientists and highly experienced biopharmaceutical leaders who have successfully developed and commercialized multiple franchises.
- This press release contains certain forward-looking statements relating to Tevogen Bio Inc.s (the Company) development and patient access of its innovations in infectious diseases and oncology.